| 摘要 |
2087606 9202515 PCTABS00010 A compound selected from the group consisting of those having formula (I) and pharmaceutically acceptable acid addition salts thereof, wherein R1 and R4 are independently selected from the group consisting of H and alkyl radicals having 1 to 4 carbon atoms; the R2s are each H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo; the R3s are each H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo, provided that the R2s or the R3s are alkyl radicals; the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7- or 8- positions of the quinoxaline nucleus; and R5, R6 and R7 each is located in one of the remaining 5-, 6-, 7- or 8- positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals having 1 to 3 carbon atoms. Such compounds, when administered to a mammal, provide desired therapeutic effects, such as alteration in the rate of fluid transport in the gastrointestinal tract, reduction in intraocular pressure, and increase in renal fluid flow.
|
